Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published
26 Febrero 2024 - 6:30AM
Orion Group Financial Statement documents 2023, Corporate
Governance Statement and Remuneration Report published
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL
REPORT26 FEBRUARY 2024 at 14.30 EET
Orion
Group Financial Statement documents 2023, Corporate Governance
Statement and Remuneration Report published
Orion Group's Financial Statement documents for 2023 have been
published. The documents are available in Finnish and English on
the Company's website at http://www.orion.fi/en and are attached to
this release. The Financial Statements are published in accordance
with the European Single Electronic Format (ESEF) reporting
requirements as xHTML file. The primary statements and notes to the
Consolidated financial statements have been labelled with XBRL
tags. Authorised Public Accountants KPMG Oy Ab has provided an
independent auditor’s reasonable assurance report on Orion’s ESEF
Financial Statements in accordance with ISAE 3000.
The official Financial Statement documents in accordance with
the requirements of the Finnish Accounting Act and the Companies
Act, which include the Financial Statements, the Report by the
Board of Directors and the Auditor's Report are available in
Finnish at http://www.orion.fi/yhtiokokous2024.
Orion's Corporate Governance Statement 2023 and Remuneration
Report 2023, both adopted by the Board of Directors, have also been
published as separate reports in Finnish and English on the
Company's website at http://www.orion.fi/en and are attached to
this release.
Orion Corporation
Olli HuotariSVP,
Corporate Functions |
|
Terhi OrmioVP,
Communications |
|
Contact
person:Tuukka Hirvonen, Investor Relationstel. +358
10 426 2721
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandhttp://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and self-care products. The core therapy areas of our
pharmaceutical R&D are oncology and pain. Proprietary products
developed by Orion are used to treat cancer, neurological diseases
and respiratory diseases, among others. Orion's net sales in 2023
amounted to EUR 1,190 million and the company had about 3,600
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
- Orion_Corporate_Governance_Statement_2023
- Orion_Remuneration_report_2023
- Orion_Financial_Statement_documents_2023
- 74370029VAHCXDR7B745-2023-12-31-en
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024